# Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

> **NCT01111825** · PHASE1,PHASE2 · COMPLETED · sponsor: **Puma Biotechnology, Inc.** · enrollment: 99 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Neratinib

## Key facts

- **NCT ID:** NCT01111825
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2018-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01111825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01111825, "Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01111825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*